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Abstract
Background: There are many barriers to patient participation in randomised controlled trials of
cancer treatments. To increase participation in trials, strategies need to be identified to overcome
these barriers. Our aim was to assess the effectiveness of interventions to overcome barriers to
patient participation in randomised controlled trials (RCTs) of cancer treatments.
Methods: A systematic review was conducted. Published and unpublished studies in any language
were searched for in fifteen electronic databases, including MEDLINE, EMBASE, CINAHL and
PsycINFO, from inception to the end of 2004.
Studies of any interventions to improve cancer patient participation in RCTs, which reported the
change in recruitment rates, were eligible for inclusion. RCTs and non-randomised controlled trials
as well as before and after studies reporting baseline rates specific to the population being
investigated were included. Data were extracted by one reviewer into structured summary tables
and checked for accuracy by a second reviewer. Each included study was assessed against a
checklist for methodological quality by one reviewer and checked by a second reviewer. A
narrative synthesis was conducted.
Results: Eight studies were identified that met the inclusion criteria: three RCTs, two non-
randomised controlled trials and three observational studies. Six of the studies had an intervention
that had some relevance to the UK. There was no robust evidence that any of the interventions
investigated led to an increase in cancer patient participation in RCTs, though one good quality
RCT found that urologists and nurses were equally effective at recruiting participants to a
treatment trial for prostate cancer. Although there was no evidence of an effect in any of the
studies, the evidence was not of sufficient quality to be able to conclude that these interventions
therefore do not work.
Conclusion: There is not a strong evidence-base for interventions that increase cancer patient
participation in randomised trials. Further research is required to evaluate the effectiveness of
strategies to increase participation in cancer treatment trials.
Published: 17 May 2006
Trials 2006, 7:16 doi:10.1186/1745-6215-7-16
Received: 30 January 2006
Accepted: 17 May 2006
This article is available from: http://www.trialsjournal.com/content/7/1/16
© 2006 Mc Daid et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Trials 2006, 7:16 http://www.trialsjournal.com/content/7/1/16
Page 2 of 10
(page number not for citation purposes)
Background
Recruitment of the required number of patients is central
to successful completion of a trial. In 2000, the NHS Plan
set the target of doubling the total proportion of cancer
patients entering clinical trials within three years.[1,2]
This target was met by 2004, when almost 11% of people
with newly diagnosed cancer participated in trials. [3]
However, this remains a small proportion of all cancer
patients. Recruitment levels vary between trials. Of 333
public and charity funded cancer randomised controlled
trials (RCTs), conducted in the UK between 1971 and
2000, one fifth recruited at least 75% of the planned sam-
ple, just over one half did not reach the planned sample
size, while one fifth recruited less than 25% of the
planned number of patients. [4]
While the research literature fails to identify in a clear, reli-
able and consistent way the barriers involved in cancer
trial participation, themes can be identified.[5] Patient
related barriers include preference for a specific treatment,
level of knowledge, concerns about randomisation and
practical issues such as distance from the clinic and trans-
portation costs. Physician and organisation related barri-
ers include lack of time, poor organisational
infrastructure, trials competing for the same patients,
identifying eligible patients, lack of awareness of ongoing
trials and preference for a particular treatment arm. How-
ever, the listing of barriers to participation in cancer trials
belies a complex situation. The barriers vary in impor-
tance in individual trials and are likely to interact in
unique ways for individual trials. These issues have been
explored from many different disciplinary perspectives
including psychology, sociology, ethics, professional edu-
cation and health policy.
This systematic review is the second part of a project,
funded by the National Cancer Research Network, which
considers how participation rates in cancer trials might be
improved. The first part of the project was a systematic
review of the literature relating to the barriers to participa-
tion in cancer trials as perceived by patients and clinicians.
[5] In the second part we aimed to investigate the evi-
dence-base for interventions to overcome barriers to trial
participation.
We were concerned specifically with strategies to increase
the participation of patients in RCTs of cancer treatments.
There is likely to be some overlap between strategies that
increase participation in cancer treatment and cancer
screening and prevention trials. However, many of the
issues that an apparently healthy individual needs to
weigh up before deciding to participate in a prevention or
screening trial would seem to be inherently different from
those that need to be considered by an individual with
cancer with the option of entering a treatment trial. Simi-
larly, while there is likely to be some overlap in strategies
that effectively increase participation in randomised and
nonrandomised studies, there are many differences. In
particular, there is evidence that being faced with the pos-
sibility of being randomised to a treatment arm as
opposed to choosing treatment on the basis of patient or
clinician preferences raises particular concerns for
patients, and indeed sometimes clinicians. [5]
An earlier systematic review of interventions to improve
recruitment to research studies considered both mock and
real scenarios, as well as patient and non-patient groups.
[6] Only studies published before 2002 were included, the
authors highlighted the possibility of missed studies and
the quality assessment was fairly limited. While studies
using a hypothetical scenario may be useful in generating
ideas as to what might be effective in a real scenario, any
interventions found to be effective in increasing willing-
ness to participate in a hypothetical trial would require
subsequent testing in a real scenario. Therefore, the deci-
sion was made in the current review to focus exclusively
on interventions directed at real trials. We were specifi-
cally interested in actual trial participation. Patient knowl-
edge and understanding[7] or the quality of clinician
communication with patients about RCTs[8] are impor-
tant outcomes in their own right. However, improvement
in these outcomes does not necessarily translate into
increased patient participation in cancer trials.[9]
We carried out a systematic review of the available evi-
dence on the effectiveness of any interventions to increase
cancer patient participation in randomised controlled tri-
als.
Methods
Search strategy
We searched fifteen databases for published and unpub-
lished studies, with no language restrictions: MEDLINE,
EMBASE, CINAHL, PsycINFO, Cochrane Database of Sys-
tematic Reviews, Cochrane Database of Methodology
Reviews, Database of Abstracts of Reviews of Effects,
Health Technology Assessment database, American Soci-
ety of Clinical Oncology Website, Health Management
Information Consortium, System for Information and
Grey literature in Europe, ISI Science Citation Index, SI
Social Science Citation Index, Sociological Abstracts,
Applied Social Sciences Index and Abstracts. The search
strategy combined groups of search terms representing
cancer trials and patient participation. (See Additional file
1 for full details of the MEDLINE search strategy which
was amended as necessary for the other databases
searched.) We also searched the reference lists of all
retrieved articles.Trials 2006, 7:16 http://www.trialsjournal.com/content/7/1/16
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Selection of eligible studies
Two reviewers independently assessed titles and abstracts
and full papers, where these were obtained. We included
studies of any interventions to improve cancer patient par-
ticipation in RCTs, which reported change in participation
rates. The primary outcome of interest was patient partic-
ipation. Therefore, for example, interventions aimed at
increasing physician participation in trials, or interven-
tions targeted at organisational change were eligible for
inclusion provided the impact on patient participation
rates was also assessed. The definition of participation var-
ied between studies and the definition used by individual
studies was accepted. We included controlled trials and
also before and after studies, provided baseline participa-
tion rates were reported specific to the population being
investigated. We contacted authors for clarification when
it was unclear whether the intervention was directed at
randomised or nonrandomised clinical trials.
One reviewer extracted data from included studies into
structured summary tables and assessed the methodolog-
ical quality of the studies. A second reviewer checked the
data and quality assessment with disagreements resolved
by discussion and consensus. We developed separate
quality checklists to assess RCTs, for each relevant study
design, based on CRD Report No.4.[10] We assessed
whether measures had been taken by the study authors to
avoid or minimise selection bias, attrition bias, perform-
ance bias and whether the study design protected against
contamination between the intervention and the compar-
ison. Studies were also assessed as to whether the nature
of the intervention was clear and whether the target of the
intervention was clearly defined. It was not appropriate to
undertake a statistical synthesis as the included studies
were very diverse; therefore we conducted a narrative syn-
thesis.
Results
Overview
We screened 3385 references and assessed 136 full papers.
Eight studies met our inclusion criteria: three RCTs; two
nonrandomised controlled prospective studies; two
observational prospective studies with a comparison
group and one before and after study (see Figure 1). The
majority of studies were excluded because there was no
intervention targeted at improving patient participation
in cancer trials. Three studies were excluded because data
on participation in randomised and non randomised tri-
als were reported together and, following contact with the
authors, no separate data were available for patient partic-
ipation in RCTs. [11-13] It was not possible to assess six
papers: one had not been received and for five papers it
was unclear whether the intervention was directed at an
RCT. [14-18]
Study characteristics
Table 1 summarises the main characteristics of the eight
included studies. We found three studies that had been
conducted in the UK or Europe, [19-21] one of which was
an RCT.[19] Two of the UK studies were concerned with
participation in the same cancer treatment trial.[19,20]
The remaining five studies were conducted in the US [22-
25] and Australia.[26] The majority of studies were con-
cerned with some aspect of the consent process. In four of
the seven studies of adults, the majority of participants
were women. Four studies included predominantly white
participants[22,23,25,26] and this information was not
reported in the remaining studies. The majority of studies
included individuals with different cancers. Only two
studies provided details of disease stage or severity and
only for subgroups of patients.[22,23] The included stud-
ies varied in quality. A summary of individual study qual-
ity is provided in Table 1 and the full quality appraisal for
individual studies is available in the full report.[27] Care
needs to be taken when comparing rates of trial participa-
tion between studies due to between study variation in
how participation was defined. In four studies, trial partic-
ipation was defined as the number of patients accrued or
enrolled but it was not clear whether this referred to the
proportion who agreed to randomisation or the propor-
tion who actually accepted their allocation. [22-25] One
study that used both measures illustrated that there can be
a considerable difference between these figures, with
actual accrual being lower than consent to randomisa-
tion.[20] A further study based participation rates on
questionnaires completed by patients, following their
Study selection process Figure 1
Study selection process.
Studies meeting inclusion criteria 
Randomised controlled trial: n=3 
Nonrandomised controlled study: n=2 
Controlled observational study: n=2 
Before and after: n=1 
Total: n=8 (9 papers) 
Excluded papers
No intervention: n=101 
No participation rates: n=13 
Not evaluative: n=5 
Hypothetical: n=2 
Total: n=121 
Full papers ordered 
n=136
Papers awaiting assessment
Not received: n=1 
Awaiting information from 
authors: n=5 
Total: n=6 
References identified (following de-duplication) and screened 
n=3385Trials 2006, 7:16 http://www.trialsjournal.com/content/7/1/16
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Table 1: Characteristics of included studies
Study details Study design Target of 
intervention 
(who received 
the intervention; 
and the number 
of trials across 
which it was 
assessed)
Patient 
Participants
Experimental 
Intervention/and 
comparator
Summary of threats to 
validity
Angiolillo et al. 
(2004)[24] United 
States
Controlled 
observational study
Parents of children 
with cancer
Four Children 
Cancer Group 
Trials
I: n = 36;
C: n = 104
Parents of children 
with acute 
leukaemia
Age of children I: 
Mean 4.9 yrs (SD 
2.5);
C: 7.8 yrs (SD 5.1)
Ethnicity not stated
Intervention: A two-stage 
process was used for one 
trial. 1. Written parental 
consent was sought for the 
induction phase of the trial 
during which all patients 
received the same induction 
chemotherapy. Written 
consent (4 weeks later) was 
then obtained for 
randomisation to one of 
four therapeutic regimens.
Comparator: Parents of 
children in the other three 
trials did not receive the 
staged approach. No further 
details provided.
A high possibility of 
selection bias due to lack of 
randomisation and no 
reported process for 
selecting individual 
participants. The 
intervention was not 
implemented in a 
standardised way. Due to 
poor reporting the risk of 
contamination was unclear. 
There was a particular risk 
of performance bias.
Coyne et al. 
(2003)[22] United 
States
Cluster randomised 
controlled trial
Adult cancer 
patients
Three trials 
(C9741; E1594; 
E2197)
I: n = 78;
C: n = 129
Breast (85%) and 
lung cancer patients
I: 92.3% female;
C 90.7% female
I: Mean 53 yrs;
C: mean 53 yrs
I: 94% white;
C: 92% white
Intervention: Easy to read 
version of the original 
written consent document 
(different for each of the 
three trials). Changes 
included text style, page 
layout, font size and 
vocabulary. Content was 
not altered. Readability was 
seventh to eighth grade 
level and length was 16 
pages.
Comparator: Original 
consent document 
(different for each of the 
three trials). E1594: 4 pages 
long and fourteenth grade 
reading level. C9741 and 
E2197: 7–8 pages long and 
twelfth to thirteenth grade 
reading level.
This was a randomised 
study. The unit of 
randomisation was at the 
institutional level and this 
was maintained for the 
statistical analysis. However, 
due to poor reporting it is 
unclear whether the study 
was properly designed to 
protect against selection 
bias. The design appeared to 
protect against 
contamination as only one 
consent statement was used 
at an individual centre.
Donovan et al. 
(2003)[19] United 
Kingdom
Randomised 
controlled trial
Adult cancer 
patients
Single trial
I: n = 75;
C: n = 75
Prostate cancer 
patients
100% male
Age not stated
Ethnicity not stated
Intervention: Nurse 
conducted information 
appointment with the 
patient to recruit to the 
trial.
Comparator: Urologist 
conducted information 
appointment with the 
patient to recruit to the 
trial.
A good quality RCT: 
appropriate randomisation, 
concealed allocation, at 
least 80% of patients 
considered at follow-up and 
ITT analysis conducted. It is 
possible that contamination 
between the two groups 
and performance bias may 
have influenced the findings.Trials 2006, 7:16 http://www.trialsjournal.com/content/7/1/16
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Donovan et al. 
(2002)[20] United 
Kingdom
Before and after Healthcare 
professionals
Single trial
Baseline: n = 30;
I1: n = 45;
I2 n = 67;
I3: n = 83;
I4: n = 155
Prostate cancer 
patients
100% male Age not 
stated
Ethnicity not stated
Intervention: Three 
successive documents§ 
regarding how best to 
recruit patients to the trial 
were circulated to 
recruiters followed by a 
training programme. 
Consent to randomisation 
was measured at baseline 
and following circulation of 
each document.
This is an uncontrolled 
study therefore there is a 
risk of factors other than 
the intervention influencing 
patient participation.
Fleissig et al. 
(2001)[21] United 
Kingdom
Nonrandomised 
controlled study
Healthcare 
professionals and 
adult cancer 
patients
Forty trials
I: n = 135;
C: n = 130
10 different cancers
I: 72% female;
C: 72% female
Age range 19–65 
yrs
I: 58% 45–64 yrs;
C: 50% 45–64 yrs
Ethnicity not stated
Intervention: Patients 
completed the Patient 
Preferences for Information 
Questionnaire, Patient 
Attitudes to Trials 
Questionnaire and 
Spielberger State Trait 
Anxiety Inventory prior to 
consultation with their 
doctor. Doctors were then 
provided with each patient's 
completed questionnaires 
(only the first 2 
questionnaires) prior to 
their consultation during 
which consent was sought 
for a specific trial.
Comparator: Patients 
completed the same 
questionnaires prior to 
consultation with their 
doctor. Doctors were not 
provided with this 
information prior to their 
consultation with individual 
patients during which 
consent was sought for a 
specific trial.
A high possibility of 
selection bias: only the 
order in which doctors 
conducted intervention and 
control group consultations 
were randomised (in blocks 
of 5 patients). The process 
by which patients were 
selected for inclusion was 
not reported. There was a 
high possibility of 
contamination as the same 
doctors were involved 
administering the 
experimental intervention 
and the comparison. The 
intervention was not 
implemented in a 
standardised way. The 
process of completing the 
questionnaires may have 
influenced patient decision-
making in both groups.
Gross et al. 
(2004)[25] United 
States
Controlled 
observational study
System level
Global target 
(National Cancer 
Institute phase II 
and III Clinical 
Trials Cooperative 
Group trials)
I: n = 4569;
C: n = 20,443 
(2,440 were in 
phase II trials)
Breast, colon, lung 
and prostate cancer 
patients
Sex not stated
Age not stated 89% 
white
Intervention: Four states 
(Illinois, Louisiana, Virginia, 
New Jersey) that enacted 
legislation or developed a 
co-operative agreement 
with health insurers in 1999 
to cover clinical trial patient 
care costs (coverage states).
Comparator: 35 states 
that had not enacted any 
policies to cover clinical trial 
patient care costs by the 
end of 2001 (non-coverage 
states)
The baseline enrolment rate 
was statistically significantly 
higher in intervention group 
than the comparator group 
introducing the risk of 
regression to the mean. 
Lack of enforcement in the 
intervention group and 
behaviour of physicians in 
the comparator states to 
compensate for lack of 
coverage could have had an 
influence.
Table 1: Characteristics of included studies (Continued)Trials 2006, 7:16 http://www.trialsjournal.com/content/7/1/16
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Paskett et al. 
(2002)[23] United 
States
Nonrandomised 
controlled study
Adult cancer 
patients, healthcare 
professionals
All trials available 
to patients in a 
given geographical 
area.
Total number of 
participants not 
stated
Breast and 
colorectal cancer 
patients
Majority female
Age not stated for I 
and C (mean age, 
which was 
reported by time 
period of 
recruitment and 
cancer type ranged 
from 62 to 75 yrs)
75% white
Intervention: There were 
four elements: 1) a rapid 
tumour reporting system, 2) 
a nurse facilitator 
responsible for alerting 
physicians about 
appropriate clinical trials for 
their patients, 3) a quarterly 
newsletter about cancer 
treatment and clinical trials 
targeted at physicians and 4) 
a health educator who 
provided community-based 
education about screening 
and treatment and trained 
lay health educators. 
Implemented in five rural 
counties in North Carolina.
Comparator: No 
intervention in five rural 
counties in South Carolina.
The risk of selection bias is 
unclear. Data on patient 
trial participation were 
obtained from medical 
records; however it was 
unclear how specific cancer 
patients within regions were 
selected or whether all 
cases were detected. The 
study was susceptible to 
contamination: improving 
participation of patients in 
all rural areas was a major 
focus of the Community 
Clinical Oncology Program 
(CCOP) and both 
geographical areas had 
active CCOP physicians.
Simes et al. 
(1986)[26] 
Australia
Randomised 
controlled trial
Adult cancer 
patients and 
healthcare 
professionals
Thirteen trials at a 
single oncology unit
I: n = 28;
C: n = 29
8 different cancers
I: 82% female;
C: 62% female
I: mean 56 yrs (31–
63 yrs);
C mean 55 yrs (40–
74 yrs)
I: 96% white;
C: 100% white
Intervention: Uniform 
policy of total disclosure of 
all information relevant to 
the trial to the patient. 
There was an opportunity 
to ask further questions. 
Information was provided 
verbally and in a written 
consent form.
Comparator: Information 
about the aims, anticipated 
results and potential 
toxicities of treatment were 
provided with details of 
treatment provided at the 
discretion of the consultant. 
There was an opportunity 
for the patient to ask 
questions. Verbal consent 
was obtained.
This was a randomised 
study though it was not 
possible to assess from the 
information reported 
whether the method of 
assignment was truly 
random and whether it was 
concealed. There was a high 
possibility of contamination 
as the same doctors were 
involved in delivering the 
experimental. Attempts 
were made to establish 
whether the intervention 
and comparison were 
standardised across patients 
though it was not possible 
to establish whether the 
method used was 
sufficiently rigorous.
I: experimental intervention, C: comparator
§Document 1 asked recruiters to present the three treatment options in a particular order and provide equivalent detail on advantages and 
disadvantages. They were asked to avoid the terms trials and 'watchful waiting' to describe monitoring and place emphasis on patients being eligible 
for all treatments; document 2 re-emphasised monitoring as an active process, eliciting and challenging patients' views if at odds with the evidence 
and re-emphasised there was no compulsion to accept treatment allocation; document 3 provided good and not so good examples of how to 
present information about treatments in an equal way.
Table 1: Characteristics of included studies (Continued)Trials 2006, 7:16 http://www.trialsjournal.com/content/7/1/16
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meeting with the doctor, stating whether they wanted to
participate. This may have overestimated the number who
actually started the trial.[21]
We synthesised two studies separately from the others as
the interventions could not be implemented in the UK;
these are only briefly summarised here. One was an RCT
conducted almost 20 years ago in Australia which investi-
gated a uniform policy of full disclosure of all relevant
information when seeking patient consent to trial partici-
pation compared with disclosure of information at the
discretion of the consultant[26] A written consent docu-
ment was completed for the former condition whereas
only verbal consent was obtained for the latter. In the UK
setting, clinical trials regulations require full disclosure of
information with written consent.[28] The second study
investigated the effect of legislation requiring health
insurers to cover clinical trial patient care costs on trial
participation rates in the US.[25] Although the funding of
trials is an important issue this study is only relevant in
settings where health insurance is widespread.
Efficacy of interventions
Across the remaining six studies there was no evidence
that any of the experimental interventions evaluated led
to an increase in cancer patient participation in RCTs com-
pared with the comparison intervention (see Table 2). A
good quality RCT, conducted in a UK setting, did find that
nurses and urologists were equally effective in recruiting
men with prostate cancer to a treatment trial with a two
and three-arm comparison though recruitment levels var-
ied between the three centres (94%, 61% and 45%).[19]
Based on a cost minimisation analysis, recruitment by
nurses was more cost-effective. This finding was
unchanged in six out of seven sensitivity analyses explor-
ing different resource scenarios, though the size of the cost
difference did change. An uncontrolled qualitative study
involving patients and recruitment staff was also under-
taken in relation to the same trial. This study found
increased participation rates following amendments to
the nature and emphasis of information provided to
potential trial participants.[20] However, given that this
was not a controlled study, the influence of other factors
on the recruitment rates cannot be excluded.
The following interventions were not associated with an
increase in trial participation: a two-stage process for seek-
ing parental consent for their child's participation in a leu-
kaemia trial compared to the standard approach;[24] a
written consent document designed to be easy to read
compared with the standard consent form; [22] providing
doctors with information on patients' individual informa-
tion needs and attitudes to trials prior to seeking consent
compared with the doctor not having this informa-
tion;[21] and a multi-component, system level interven-
tion compared with no intervention.[23] However, the
evidence is not sufficient to conclude that the interven-
tions investigated are ineffective.
In most of the studies participation levels were high in
both the intervention and the control group. Apart from
one study with low participation levels, [23] participation
rates in the control groups ranged from 68% to 88%. This
raises the question of whether there was a Hawthorne
effect i.e. that the experience of participation in a study per
se led to an increase in participation in the cancer trial.
This could have been sufficient to mask an effect of the
experimental intervention, especially given the fairly
small sample sizes in these studies. Alternatively, the par-
ticular cancer trials to which patients were being recruited
in these studies may have been trials which were easy to
recruit to and that would have had high recruitment levels
anyway. This may have lead to a ceiling effect in individ-
ual trials. None of the interventions appeared to be in
response to recruitment problems being encountered
either with the specific trials where individual trials were
being targeted or with the health professionals conducting
the recruitment where a large number of different trials
were involved. For two studies related to a trial for treat-
ment of prostate cancer the trial was described as contro-
versial and difficulties in recruitment were anticipated.
[19,20]
There is the possibility that the specific interventions
investigated do not work in the particular contexts in
which they were used. They may prove effective with a dif-
ferent patient group or in relation to a different trial. For
example, if the effect on participation levels of an 'easy to
read' informed consent form, as used in the study con-
ducted by Coyne et al., [22] had been investigated with
patients with a lower level of literacy than the women in
the study, it may have been found to be effective.
Most of the studies had methodological weaknesses.
Apart from one good quality RCT with appropriate ran-
domisation and concealment of allocation, [19] the
remaining studies were vulnerable to selection bias.
Across the studies there seemed to be a risk of underesti-
mating the effect of the interventions due to the possibil-
ity of contamination between the experimental and
comparison intervention. Contamination refers to the sit-
uation where the control or comparison group receives
part of the experimental intervention leading to
unplanned similarities between the two conditions; for
example, where the same clinicians are responsible for
delivering the experimental intervention and comparison,
knowledge of the experimental intervention may influ-
ence how the comparator is delivered. This can lead to a
dilution of any effect of the experimental intervention.
Apart from one included study that minimised the riskTrials 2006, 7:16 http://www.trialsjournal.com/content/7/1/16
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through study design, [22] there was a risk of contamina-
tion across all studies.
Discussion
Overall there is not a strong evidence-base for interven-
tions that increase patient participation in cancer treat-
ment trials. Despite the large volume of research that
exists on barriers to participation in cancer trials[5], we
found only a small body of research on interventions to
overcome these barriers. And despite the plethora of
potential barriers to participation that have been identi-
fied, only a small number of barriers were addressed. Most
of the interventions were concerned with the consent
process, though the specific aspects addressed varied,
ranging from a fairly simple intervention to make a con-
sent form more readable to more complex approaches tai-
loring the information provided to potential participants.
In addition, they were mainly pragmatic interventions;
this mirrors the research on barriers to participation in
cancer trials which is generally not theoretically driven.
[5]
There was no evidence that any of the interventions inves-
tigated led to an increase in cancer patient participation in
clinical trials. However, the evidence was not of sufficient
quality to be able to conclude that these interventions
therefore are not effective. Overall the studies had a range
of methodological weaknesses and in most of the studies
there was a risk of the effect of the intervention being
underestimated. The barriers to recruitment may be
numerous, complex and probably interact in a unique
way in relation to individual trials. In contrast, most stud-
ies investigated interventions targeted at one aspect of
recruitment in isolation. This is not surprising as it is
probably the most straightforward way to evaluate an
intervention. However, if the intervention did not target
the key barrier to participation in a particular trial, it may
not show any evidence of effectiveness in that particular
situation. Indeed, some cancer trials experience rapid and
successful recruitment, which may relate, for example, to
the particular treatment being investigated.[29]
The findings of this systematic review are similar to previ-
ous systematic reviews with an overlapping scope. In one
review of interventions to increase participation in mock
and real trials, in healthy individuals and all patient
groups, over 75% of the included studies found no evi-
dence of an effect on participation.[6] In a review of inter-
ventions to improve research participants' understanding
during the informed consent process a similar proportion
of studies found no evidence of an effect on accrual to real
or mock trials.[7] The quality assessment in both reviews
was fairly limited and possible reasons for the lack of
effect in so many of the studies were not explored.
Strengths and weaknesses of the review
We searched for evidence from a wide range of sources on
any interventions targeted at improving patient participa-
tion in randomised cancer treatment trials or interven-
tions aimed at making the process easier or more efficient.
A range of study designs were included. However, given
the nature of the topic, no relevant indexing terms were
available for any of the databases searched, and the search
strategy was heavily reliant on textword searching. This
meant that the searches were limited to the terms used by
authors in the title and abstract fields of each reference.
Because of this, there is always the possibility that studies
may have been missed.
Table 2: Participation rates
Study details Intervention Comparator
Angiolillo et al. (2004)[24] 77% 88%*
Coyne et al. (2003)[22] 75% 68%*
Donovan et al. (2003)[19] 67% 71%*
Donovan et al. (2002)[20] Baseline 30–40%
Intervetion 1 51%
Intervention 2 58%
Intervention 3 61%
Intervention 4 70%
No comparator
Fleissig et al. (2001)[21] 81% 74%*
Paskett et al. (2002)[23] Breast
1991 15% (n = 24);
1996 6% (n = 14)
Colorectal
1991** 4%
1996 5%
Breast
1991 6% (n = 6);
1996 50% (n = 16)
Colorectal
1991** 5%
1996 0%
*only those studies with an asterisk assessed statistical significance, all of these were non significant.
** number of patients not availableTrials 2006, 7:16 http://www.trialsjournal.com/content/7/1/16
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We focused on interventions to improve participation in
trials involving cancer patients. Studies of interventions
with other patient groups may provide useful information
that might be transferable to cancer treatment trials.
Therefore the review may have excluded studies of
patients with other conditions that might have high-
lighted interventions worthy of further investigation with
cancer patients.
Conclusion
A more robust evidence-base for strategies to maximise
patient participation in cancer trials is required. Preferably
RCTs should be used to evaluate the effectiveness of inter-
ventions. However, we recognise that there are many prac-
tical barriers to carrying out RCTs of interventions to
increase trial participation within the setting of a cancer
treatment RCT.
There are a number of issues that need to be considered in
future studies. The interventions in this field are effec-
tively complex interventions and would benefit from
being treated as such.[30,31] This could include use of
qualitative as well as quantitative methods and piloting to
define the intervention. Similar methods could be used to
assess whether the intervention is being used in the appro-
priate context in terms of the barriers to patient participa-
tion in the trial/s being considered. One of the included
studies effectively used such an approach to investigate
the barriers to patient participation specific to the cancer
trial.[20] Examples of such approaches are available in
other areas of research.[32,33]
The risk of contamination between the experimental and
comparison intervention needs to be assessed and taken
into consideration. Using cluster randomised trials or
increasing sample size are possible approaches[34,35]
The possibility of clustering where more than one health
professional delivers the intervention also needs to be
taken into consideration when estimating the required
sample size.[36] The problem raised by a lack of blinding
of healthcare professionals cannot be avoided as blinding
is not possible in these studies. However measures could
perhaps be taken to systematically document the imple-
mentation of the intervention and comparison.
Future studies also need to consider the potential influ-
ence of social and ethnic background and disease related
factors such as severity or stage of disease, social and eth-
nic background on the effectiveness of interventions to
increase patient participation in cancer trials. Such infor-
mation was frequently not provided in the studies
included in this review.
Given the paucity of studies investigating interventions
targeted specifically at cancer patients, it would be helpful
to consider inclusion of interventions with different
patient groups in future updates. It may also be beneficial
to examine whether interventions to improve recruitment
to nonrandomised trials exist which may be applicable to
randomised trials.
The majority of included studies examined interventions
targeted at the informed consent process. Where this proc-
ess is the target of an intervention, trial participation can-
not be considered in isolation from the quality of the
informed consent process. The dangers of coercion when
tailoring the information to maximise patient trial partic-
ipation rates requires careful consideration.[20,37,38]
Work has been carried out to develop a questionnaire to
assess the quality of the informed consent process.[39]
Some of the included studies assessed understanding or
knowledge as well as trial participation as an outcome.
However the extent to which understanding or knowledge
are an indicator for the quality of the consent process is
unclear. Future primary studies directed at the informed
consent process should consider assessing the quality of
the process as well as the impact on participation.
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